Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of secukinumab for psoriatic arthritis and non-radiographic axial spondyloarthritis
CTR20222505Phase 3Active
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), sponsored by Novartis. Started Nov 2022; status: active.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on CTR20222505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222505.